60 results found.

Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent S Clinical Trial using soy isoflavones; laboratory biomarker analysis; survey administration

National Cancer Institute (NCI) - Recruiting 19 years to 79 years.
- A Phase II Trial of Preoperative Soy Isoflavone Supplementation and Molecular Markers in the Prevention of Head and Neck Squamous Carcinoma.
soy isoflavones; laboratory biomarker analysis; survey administration

Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck Clinical Trial using CC-115

Celgene Corporation - Recruiting 18 years or older.
- A Phase 1a/b, Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Dual DNA-PK and TOR Kinase Inhibitor, CC-115, Administered Orally to Subjects With Advanced Solid Tumors, and Hematologic Malignancies..
CC-115

Head and Neck Neoplasms Clinical Trial using methotrexate; afatinib

Boehringer Ingelheim - Recruiting 18 years or older.
- A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy.
methotrexate; afatinib

Head and Neck Neoplasms Clinical Trial using Placebo; Afatinib

Boehringer Ingelheim - Recruiting 18 years or older.
- A Randomised, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Afatinib (BIBW 2992) as Adjuvant Therapy After Chemo-radiotherapy in Primary Unresected Patients With Stage III, IVa, or IVb Loco-regionally Advanced Head and Neck Squamous Cell Carcinoma.
Placebo; Afatinib

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Clinical Trial using tivantinib; cetuximab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase II Trial of ARQ 197 (Tivantinib) /Cetuximab Versus Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer.
tivantinib; cetuximab; laboratory biomarker analysis

Head and Neck Cancer Clinical Trial using MEHD7945A; cisplatin; 5-FU; carboplatin; paclitaxel

Genentech - Recruiting 18 years or older.
- A Phase 1b Open-Label Study of the Safety and Pharmacokinetics of MEHD7945A in Combination With Either Cisplatin and 5-FU or Paclitaxel and Carboplatin in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
MEHD7945A; cisplatin; 5-FU; carboplatin; paclitaxel

Cetuximab-induced Papulopustular (Acneiform) Rash Who Have, or Me Clinical Trial using Topical Dapsone 5% Gel; Moisturizer; oral antibiotics

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase III Randomized Double-blind Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT.
Topical Dapsone 5% Gel; Moisturizer; oral antibiotics

Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (RM Clinical Trial using BYL719+cetuximab; cetuximab

Novartis - Recruiting 18 years or older.
- A Phase Ib Dose Escalation/Randomized Phase II, Multicenter, Open-label Study of BYL719 in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
BYL719+cetuximab; cetuximab

Squamous Cell Carcinoma, or Head and Neck Cancer Clinical Trial using EGFR Antisense DNA

The University of Texas Health Science Center at San Antonio - Recruiting 18 years or older.
- Safety and Efficacy of Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma.
EGFR Antisense DNA

Head and Neck Cancer, or Squamous Cell Carcinoma of the Head and Clinical Trial using Cisplatin; Docetaxel; Erlotinib; Placebo; Carboplatin

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Randomized, Placebo-Controlled, Phase 2 Study of Docetaxel And Cisplatin With Or Without Erlotinib In Patients With Metastatic Or Recurrent Squamous Cell Carcinoma Of the Head And Neck.
Cisplatin; Docetaxel; Erlotinib; Placebo; Carboplatin

Head and Neck Squamous Cell Carcinoma Clinical Trial using AFATINIB; Placebo of AFATINIB

Centre Leon Berard - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy of Afatinib (BIBW2992) in Maintenance Therapy After Post- Operative Radio-chemotherapy in Squamous-cell Carcinoma of the Head and Neck: GORTEC 2010-02.
AFATINIB; Placebo of AFATINIB

Carcinoma, Squamous Cell of Head and Neck Clinical Trial using Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery

The University of Texas Health Science Center at San Antonio - Recruiting 18 years or older.
- A Phase II Study of Induction Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A) in Patients With Locally Advanced Head and Neck Cancer (CTRC# 11-36).
Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery

Head and Neck Squamous Cell Carcinoma Clinical Trial using Paclitaxel; Carboplatin; Cetuximab; Docetaxel; Cisplatin; Fluorouracil; Radiotherapy (RT); Chemotherapy

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Randomized Phase II Trial Contrasting Weekly Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma.
Paclitaxel; Carboplatin; Cetuximab; Docetaxel; Cisplatin; Fluorouracil; Radiotherapy (RT); Chemotherapy

Head and Neck Cancer Clinical Trial using Docetaxel; Cisplatin; Cetuximab; Carboplatin

Stanford University - Recruiting 16 years or older.
- Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With SCCHN.
Docetaxel; Cisplatin; Cetuximab; Carboplatin

Squamous Cell Carcinoma of the Oral Cavity, or Squamous Cell Carc Clinical Trial using GC4419

Galera Therapeutics, Inc. - Recruiting 18 years or older.
- A Phase 1 Dose Escalation Study of GC4419 in Combination With Radiation and Chemotherapy for Squamous Cell Cancers of the Head and Neck..
GC4419

Head and Neck Cancer, Oral Cavity Cancer, or Oropharyngeal Cancer Clinical Trial using Valproic Acid

Instituto do Cancer do Estado de Sao Paulo - Recruiting N/A to 65 years.
- Efficacy Evaluation of the Combination of Valproic Acid and Standard Platinum-based Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma.
Valproic Acid

Carcinoma, Squamous Cell of Head and Neck Clinical Trial using VTX-2337; Carboplatin; Cisplatin; 5-fluorouracil; Placebo

VentiRx Pharmaceuticals Inc. - Recruiting 18 years or older.
- A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination With VTX 2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.
VTX-2337; Carboplatin; Cisplatin; 5-fluorouracil; Placebo

Carcinoma Clinical Trial

Onkovis GmbH - Recruiting N/A or older.
- Open, Multicenter Observational Study of Docetaxel Utilized in Mono- or Combination Therapy for Treatment of Breast Cancer, NSCLC, Prostate Carcinoma, Adenocarcinoma of Stomach and Advanced Squamous Cell Carcinoma of Head/Neck Region..

Recurrent, or Head and Neck Cancer Clinical Trial using SBRT; Cetuximab; Docetaxel

University of Pittsburgh - Recruiting 18 years or older.
- Randomized Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN).
SBRT; Cetuximab; Docetaxel

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Clinical Trial using afatinib; placebo; laboratory biomarker analysis

Eastern Cooperative Oncology Group - Recruiting 18 years or older.
- A Randomized, Placebo Controlled Phase II Trial of Afatinib (BIBW2992) as Adjuvant Therapy Following Chemoradiation in Patients With Head and Neck Squamous Cell Carcinoma at High Risk of Recurrence.
afatinib; placebo; laboratory biomarker analysis

Head and Neck Squamous Cell Carcinoma Clinical Trial using IMRT; PET/CT; Docetaxel; Fluorouracil; Cisplatin

Lithuanian University of Health Sciences - Recruiting 18 years to 75 years.
- Assessing Tumor Response and IMRT Treatment Planning After Induction Chemotherapy Based on FDG-PET/CT for Locally Advanced Head and Neck Squamous Cell Carcinoma..
IMRT; PET/CT; Docetaxel; Fluorouracil; Cisplatin

Head and Neck Cancer Clinical Trial using 6 weeks of Radiotherapy; 5 weeks of Radiotherapy

University of California, Davis - Recruiting 18 years or older.
- Phase II Trial Of Induction Chemotherapy Followed By Attenuated Chemoradiotherapy For Locally Advanced Head And Neck Squamous Cell Carcinoma Associated With Human Papillomavirus (HPV).
6 weeks of Radiotherapy; 5 weeks of Radiotherapy

Carcinoma, Squamous Cell, Head and Neck Neoplasms, or Oropharynge Clinical Trial using Assessment of Oral HPV Infection

UNC Lineberger Comprehensive Cancer Center - Recruiting 18 years or older.
- Monitoring of Oral HPV Infection in HPV-positive Oropharyngeal Squamous Cell Carcinoma During and After Chemoradiotherapy (CRT).
Assessment of Oral HPV Infection

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Clinical Trial using TLR8 agonist VTX-2337; cetuximab; laboratory biomarker analysis; pharmacogenomic studies

University of Washington - Recruiting 18 years or older.
- Phase I Clinical Trial of VTX-2337, a Small Molecule Toll-Like Receptor 8 (TLR8) Agonist in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (SCCHN).
TLR8 agonist VTX-2337; cetuximab; laboratory biomarker analysis; pharmacogenomic studies

Head and Neck Cancer Clinical Trial using Everolimus escalating dose; Everolimus or Placebo

University of Chicago - Recruiting 18 years to 89 years.
- Selection of Chemoradiotherapy Based on Response to Induction Chemotherapy - a Phase II Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck.
Everolimus escalating dose; Everolimus or Placebo

Mouth Neoplasms, Head and Neck Neoplasms, Tongue Neoplasms, or Ca Clinical Trial using Rapamycin; Biopsy; Dynamic CT Perfusion; Positron Emission Tomography; Measurement Serum Cytokines

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 80 years.
- A Pilot Trial Targeting mTOR as a Novel Mechanism-Based Neoadjuvant Therapy for Head and Neck Cancer.
Rapamycin; Biopsy; Dynamic CT Perfusion; Positron Emission Tomography; Measurement Serum Cytokines

Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Nec Clinical Trial using ADXS11-001 (ADXS-HPV)

Mount Sinai School of Medicine - Recruiting 18 years or older.
- Window of Opportunity Trial of Neoadjuvant ADXS 11-001 Vaccination Prior to Robot -Assisted Resection of HPV-Positive Oropharyngeal Squamous Cell Carcinoma.
ADXS11-001 (ADXS-HPV)

Squamous Cell Carcinoma of the Head and Neck Clinical Trial using Cabazitaxel; Methotrexate

Cliniques universitaires Saint-Luc- Universit‚ Catholique de Louvain - Recruiting 18 years or older.
- Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-based Therapy..
Cabazitaxel; Methotrexate

Recurrent Squamous Cell Carcinoma of the Nasopharynx, or Stage IV Clinical Trial using Akt inhibitor MK2206; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Multicenter Phase II Study of MK-2206 in Previously Treated Patients With Recurrent and Metastatic Nasopharyngeal Carcinoma.
Akt inhibitor MK2206; pharmacological study; laboratory biomarker analysis

Squamous Cell Carcinoma of the Hypopharynx Stage III, Squamous Ce Clinical Trial using Docetaxel; Cisplatin; 5-fluorouracil; Cetuximab Induction; Cetuximab Radioimmunotherapy; Boost irradiation

Arbeitsgemeinschaft medikamentoese Tumortherapie - Recruiting 18 years to 75 years.
- Randomised Phase II Pilot Study: Induction Chemotherapy With Docetaxel, Cisplatin and Cetuximab Versus Docetaxel, Cisplatin and 5 FU Followed by Radiotherapy With Cetuximab for Locally Advanced or Not Resectable Carcinoma of the Head and Neck.
Docetaxel; Cisplatin; 5-fluorouracil; Cetuximab Induction; Cetuximab Radioimmunotherapy; Boost irradiation

Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III S Clinical Trial using cisplatin; docetaxel; cetuximab; laboratory biomarker analysis; quality-of-life assessment; intensity-modulated radiation therapy

Radiation Therapy Oncology Group - Recruiting 18 years or older.
- Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck.
cisplatin; docetaxel; cetuximab; laboratory biomarker analysis; quality-of-life assessment; intensity-modulated radiation therapy

Platinum Pre-treated Recurrent or Metastatic Head and Neck Squamo Clinical Trial using Paclitaxel; Buparlisib; Buparlisib Placebo

Novartis - Recruiting 18 years or older.
- Double Blind, Placebo Controlled Study Assessing the Efficacy of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Patients With Platinum Pre-treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).
Paclitaxel; Buparlisib; Buparlisib Placebo

Oral Mucositis Clinical Trial using SGX942; Placebo

Soligenix - Recruiting 18 years or older.
- A Phase 2,Double-Blind, Randomized, Placebo-Controlled, Dose Escalating, Multicenter Study of SGX942 For the Attenuation of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck.
SGX942; Placebo

Head and Neck Squamous Cell Carcinoma Clinical Trial using Standard RT; Hypofractionated RT

Groupe Oncologie Radiotherapie Tete et Cou - Recruiting 70 years or older.
- Non Inferiority Randomized Trial of Standard Radiotherapy Versus Hypofractionated Split Course Radiotherapy in Elderly Vulnerable Patients With Inoperable Head and Neck Squamous Cell Carcinoma.
Standard RT; Hypofractionated RT

Oral Cancer, Oropharynx Cancer, or Hypopharynx Cancer Clinical Trial using IMRT 75 Gy; Conventional radiotherapy 70 Gy; concomitant cisplatin

Groupe Oncologie Radiotherapie Tete et Cou - Recruiting 18 years or older.
- Phase III Trial of Intensity-modulated Radiotherapy Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma.
IMRT 75 Gy; Conventional radiotherapy 70 Gy; concomitant cisplatin

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Clinical Trial using docetaxel; cisplatin; carboplatin; fluorouracil; bevacizumab

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer.
docetaxel; cisplatin; carboplatin; fluorouracil; bevacizumab

Squamous Cell Carcinoma of the Head and Neck Clinical Trial using docetaxel - cisplatin - 5-fluorouracil; radiotherapy; cetuximab; cisplatin

Gruppo Oncologico del Nord-Ovest - Recruiting 18 years or older.
- Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin.
docetaxel - cisplatin - 5-fluorouracil; radiotherapy; cetuximab; cisplatin

Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III S Clinical Trial using cetuximab; intensity-modulated radiation therapy; ipilimumab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase Ib Trial of Concurrent Cetuximab (ERBITUXr) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOYr) in Locally Advanced Head and Neck Cancer.
cetuximab; intensity-modulated radiation therapy; ipilimumab; laboratory biomarker analysis

Head and Neck Cancer Clinical Trial using Cetuximab; Radiation Therapy

University of Cincinnati - Recruiting 18 years or older.
- Phase II Trial of Post-operative or Definitive Concurrent Radiation and Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck.
Cetuximab; Radiation Therapy

Carcinoma, Squamous Cell Clinical Trial using EGFR Antisense DNA

University of Pittsburgh - Recruiting 18 years or older.
- Safety and Efficacy Evaluation of Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma.
EGFR Antisense DNA

Carcinoma, Squamous Cell of Head and Neck Clinical Trial using Afatinib; Observation

European Organisation for Research and Treatment of Cancer - EORTC - Recruiting 18 years or older.
- Neoadjuvant Afatinib Based Treatment Strategies Followed by Surgery in Squamous Cell Carcinoma of the Head and Neck: an EORTC NOCI-HNCG Window Study..
Afatinib; Observation

Squamous Cell Carcinoma of the Head and Neck Clinical Trial using Olaparib; Cetuximab; Radiation Therapy

University of Colorado, Denver - Recruiting 18 years or older.
- Phase I Trial of Olaparib (AZD2281) in Combination With C225 and Radiation Therapy in Patients With Locally Advanced, Stage IVA-B Squamous Cell Carcinomas of the Head/Neck With Heavy Smoking Histories.
Olaparib; Cetuximab; Radiation Therapy

Head and Neck Cancer, or Head and Neck Squamous Cell Carcinoma Clinical Trial using Cyclophosphamide; Cetuximab

Masonic Cancer Center, University of Minnesota - Recruiting 18 years or older.
- Potentiation of Cetuximab by Tregs Depletion With Metronomic Cyclophosphamide in Metastatic Squamous Cell Cancers of Head and Neck.
Cyclophosphamide; Cetuximab

Head and Neck Squamous Cell Carcinoma Clinical Trial using Resistance Exercise Training (RET)

University of Michigan Cancer Center - Recruiting 18 years or older.
- Benefits of Resistance Exercise Training in Locally Advanced Head and Neck Cancer Patients Undergoing Organ-Preserving Definitive Therapy.
Resistance Exercise Training (RET)

Stage I Squamous Cell Carcinoma of the Oropharynx, Stage II Squam Clinical Trial using questionnaire administration; quality-of-life assessment

University of Chicago - Recruiting 18 years or older.
- Patient Preferences in Head and Neck Cancer Treatment Decisions - a Pilot Study of the Durability of Patient Priorities.
questionnaire administration; quality-of-life assessment

Squamous Cell Carcinoma of the Head and Neck Clinical Trial using Afatinib; Paclitaxel; Carboplatin; Cisplatin; Intensity Modulated Radiation Therapy

Sidney Kimmel Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy Followed By Standard Chemoradiation In HPV-Negative or High-risk HPV-Positive Locally Advanced Stage III/IVa/IVb HNSCC.
Afatinib; Paclitaxel; Carboplatin; Cisplatin; Intensity Modulated Radiation Therapy

Stage III Squamous Cell Carcinoma of the Oropharynx, or Stage IV Clinical Trial using vorinostat; cisplatin; radiation therapy; Correlative Studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase I Trial Of Vorinostat In The Treatment Of Advanced Laryngeal, Hypopharyngeal, Nasopahryngeal And Oropharyngeal Squamous Cell Carcinoma Of The Head And Neck..
vorinostat; cisplatin; radiation therapy; Correlative Studies

Head and Neck Cancer Clinical Trial using Cetuximab; 50-60 Gy and 70 Gy

University of Michigan Cancer Center - Recruiting 70 years or older.
- Phase II Study of RT Concurrent w/ Cetuximab in Patients w/ Locally Advanced Head & Neck SCC Who Do Not Qualify For Standard Chemotherapy Due To Age >70 Or Co-Morbidities.
Cetuximab; 50-60 Gy and 70 Gy

Squamous Cell Carcinoma of the Head and Neck Clinical Trial using 18F-EF5; Pretreatment PET/CT-scan (performed two times)

Turku University Hospital - Recruiting 18 years to 80 years.
- Reproducibility of Intratumor Distribution of 18F-EF5 in Head and Neck Cancer.
18F-EF5; Pretreatment PET/CT-scan (performed two times)

Head and Neck Cancer, or Squamous Cell Carcinoma of the Head and Clinical Trial using Carboplatin; Paclitaxel; Lapatinib; Cisplatin; Ipsilateral Radiation; Bilateral Radiation; Transoral Surgery

UNC Lineberger Comprehensive Cancer Center - Recruiting 18 years or older.
- Multimodality Risk Adapted Therapy Including Carboplatin/Paclitaxel/Lapatinib as Induction for Squamous Cell Carcinoma of the Head and Neck Amenable to Transoral Surgical Approaches.
Carboplatin; Paclitaxel; Lapatinib; Cisplatin; Ipsilateral Radiation; Bilateral Radiation; Transoral Surgery

Primary Non-operated Squamous Cell Carcinoma of Oral Cavity, Prim Clinical Trial using video fluoroscopy; extra imaging; scoring acute toxicity; scoring of late toxicity; scoring quality of life (QOL)

University Hospital, Ghent - Recruiting 18 years or older.
- Adaptive, Image-guided, Intensity-modulated Radiotherapy for Head and Neck Cancer in the Reduced Volumes of Elective Neck: a Multicenter, Two-arm, Randomized Phase II Trial..
video fluoroscopy; extra imaging; scoring acute toxicity; scoring of late toxicity; scoring quality of life (QOL)

Recurrent and Second Primary Squamous Cell Carcinoma of the Oral Clinical Trial using [18F]FDG-PET-voxel intensity-based IMRT

University Hospital, Ghent - Recruiting 18 years or older.
- A Feasibility Study on Adaptive 18F-FDG-guided Radiotherapy for Recurrent and Second Primary Head and Neck Cancer in the Previously Irradiated Territory..
[18F]FDG-PET-voxel intensity-based IMRT

Head and Neck Cancer Clinical Trial using DCE-MRI, DW-MRI and MRS

Oregon Health and Science University - Recruiting 18 years or older.
- Pilot Study of DCE-MRI, DW-MRI, and MRS in the Assessment of Head and Neck Cancer Response to Chemo-radiation.
DCE-MRI, DW-MRI and MRS

Head and Neck Cancer Clinical Trial using Nimotuzumab; Cisplatin; Radiation

National Cancer Centre, Singapore - Recruiting 21 years to 70 years.
- Phase II Study of Nimotuzumab (TheraCim-hR3) Concurrent With Cisplatin/Radiotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC).
Nimotuzumab; Cisplatin; Radiation

Head and Neck Squamous Cell Carcinoma Clinical Trial using Tadalafil; Placebo

Sidney Kimmel Comprehensive Cancer Center - Recruiting 21 years or older.
- A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract.
Tadalafil; Placebo

Locally Advanced Squamous Cell Carcinoma of the Head and Neck Reg Clinical Trial using Integrated FDG PET/CT

University Hospital, Antwerp - Recruiting 18 years or older.
- Clinical Value of Combined [18F]Fluoro-2-deoxy-D-glucose (FDG) PET/CT Imaging in Response Evaluation After Radiochemotherapy in Patients With Potentially Operable Locally Advanced Head and Neck Squamous Cell Carcinoma..
Integrated FDG PET/CT

Head and Neck Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, or Clinical Trial using cetuximab (associated with radiotherapy); cisplatin (associated to radiotherapy)

Azienda USL 4 Prato - Recruiting 18 years or older.
- Multiinstitutional Open Label Randomized Phase II Study Comparing Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy as Firstline Treatment for Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-NHSCC).
cetuximab (associated with radiotherapy); cisplatin (associated to radiotherapy)

Squamous Cell Carcinoma of the Head, or Squamous Cell Carcinoma o Clinical Trial using TPF induction chemotherapy; TPF experimental; Standard Radiochemotherapy (HART)

Charite University, Berlin, Germany - Recruiting 18 years or older.
- Randomized Phase II Study of Two Different Regimens of TPF Induction Chemotherapy Regimen Followed by Radiation Therapy Plus Cetuximab (TPF-CET-HART) vs. HART and Cis-platinum, 5-FU (PF-HART) in Patients With Locally Advanced Unresectable Squamous Cell Carcinomas of the Head and Neck.
TPF induction chemotherapy; TPF experimental; Standard Radiochemotherapy (HART)

Squamous Cell Carcinoma, or Head and Neck Cancer Clinical Trial using MAGE-A3 HPV-16 vaccine

University of Maryland - Recruiting 18 years or older.
- A Phase 1 Open Label, Dose Escalation Study to Evaluate the Effect of Four Doses of MAGE-A3/HPV 16 Trojan Peptides 0001 and 0002 Administered Subcutaneously.
MAGE-A3 HPV-16 vaccine

Squamous Cell Carcinoma of the Head and Neck Clinical Trial using Erlotinib clorhidrate; Cisplatin; Radiation therapy

Grupo de Investigaci¢n Cl¡nica en Oncolog¡a Radioterapia - Recruiting 18 years to 70 years.
- Phase I/II Trial of Erlotinib, Radiation Therapy, and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck.
Erlotinib clorhidrate; Cisplatin; Radiation therapy